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The cytokine macrophage migration inhibitory factor (MIF) is an important component of the early proin-
ﬂammatory response of the innate immune system. However, the antimicrobial defense mechanisms mediated
by MIF remain fairly mysterious. In the present study, we examined whether MIF controls bacterial uptake
and clearance by professional phagocytes, using wild-type and MIF-deﬁcient macrophages. MIF deﬁciency
did not affect bacterial phagocytosis, but it strongly impaired the killing of gram-negative bacteria by macro-
phages and host defenses against gram-negative bacterial infection, as shown by increased mortality in a
Klebsiella pneumonia model. Consistent with MIF’s regulatory role of Toll-like 4 expression in macrophages,
MIF-deﬁcient cells stimulated with lipopolysaccharide or Escherichia coli exhibited reduced nuclear factor κB
activity and tumor necrosis factor (TNF) production. Addition of recombinant MIF or TNF corrected the
killing defect of MIF-deﬁcient macrophages. Together, these data show that MIF is a key mediator of host
responses against gram-negative bacteria, acting in part via a modulation of bacterial killing by macrophages.
Keywords. Macrophage migration inhibitory factor; Macrophage; Phagocytosis; Bacterial killing; Gram-
negative Bacteria.
Macrophage migration inhibitory factor (MIF) is a
pleiotropic cytokine with broad cellular and tissue dis-
tribution. Initially described as an effector molecule of
the adaptive immune system, MIF has now also been
shown to be an integral part of the early cytokine re-
sponse of the innate immune system. Constitutively
expressed and rapidly released by innate immune cells
(monocytes, macrophages, dendritic cells, and
neutrophils) on exposure to danger signals, MIF pro-
motes cell survival and proliferation and vigorous in-
ﬂammatory and immune responses [1].
Cellular activation by MIF is mediated by a receptor
complex consisting of CD74, acting primarily as the
MIF binding moiety; CD44; CXCR2; and CXCR4 (the
signal transducer components of the receptor com-
plex) [2–5]. On receptor binding, MIF activates the ex-
tracellular signal-regulated kinase (ERK1/2), the p38
mitogen-activated protein kinase (MAPK), and the
phosphoinositide-3-kinase/Akt (PI3K/Akt) signaling
pathways [6–8]. At a molecular level, MIF mediates its
biological effects via intracellular interactions with
p53, CSN5/JAB-1, and ribosomal protein S19 [9–11].
MIF promotes proinﬂammatory and innate immune
responses of myeloid cells through different mecha-
nisms. In monocytes and macrophages, MIF sustains
the expression of Toll-like receptor 4 (TLR4), and
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therefore the responsiveness to lipopolysaccharide (LPS) and
gram-negative bacteria [12, 13]. It also functions as an inactivator
of p53-mediated LPS-induced cell death [14] and counterregu-
lates the antiinﬂammatory and immunosuppressive effects of
glucocorticoids in part by inhibiting steroid-induced MAPK
phosphatase-1 (MKP-1) expression [15]. Numerous preclinical
and clinical studies have implicated MIF in host defenses
against bacterial invasion and in the pathogenesis of sepsis [1,
16–22]. MIF blood levels are elevated in septic patients and are
associated with dysregulated adrenal function, expression of
proinﬂammatory cytokines, disease severity, and patient’s
outcome [20, 23, 24]. Consistent with an important role for
MIF in human sepsis, functional polymorphisms of the MIF
gene promoter have recently been shown to inﬂuence the sus-
ceptibility to, severity of, and outcome of pneumococcal and
meningococcal sepsis and streptococcal pneumonia [25–27].
Despite a large body of evidence indicating that MIF is an
important effector molecule of the host defense response
against bacterial infections, very little is known in terms of the
antimicrobial defense mechanisms mediated by MIF. In par-
ticular, no information is available regarding uptake and clear-
ance of bacteria by phagocytic innate immune cells. To ﬁll
that gap, we studied the phagocytosis and killing of a large
panel of gram-negative (Escherichia coli O11, O18, and J5;
Klebsiella pneumoniae; and Pseudomonas aeruginosa) and
gram-positive (Streptococcus mitis, Streptococcus pyogenes, and
Staphylococcus aureus AW7 and P8) bacterial strains by wild-
type and MIF-deﬁcient macrophages. We report that MIF
deﬁciency did not affect bacterial phagocytosis but strongly
impaired the killing of E. coli and K. pneumoniae by macro-
phages and host defenses against gram-negative infection, as
shown by increased mortality in a Klebsiella pneumonia
model. MIF-deﬁcient macrophages exhibited impaired TLR4
signaling with reduced nuclear factor κB (NF-κB) activity and
tumor necrosis factor (TNF) production.
MATERIALS AND METHODS
Mouse and Cells
RAW 264.7 macrophages were cultured in Roswell Park
Memorial Institute (RPMI) 1640 medium containing 2 mM
glutamine (Invitrogen, Basel, Switzerland) and 10% (v/v) heat-
inactivated fetal calf serum (FCS; Seromed, Berlin, Germany)
[12]. RAW 264.7 macrophages were transfected with either
empty or MIF antisense pBK plasmids (Stratagene, La Jolla,
CA). Stably transfected clones were obtained by limited dilu-
tion and selection, using Geneticin (Invitrogen). Two clones
of MIF-deﬁcient RAW 264.7 macrophages (designated as AS
2.8 and AS 2.23) expressing markedly reduced levels of MIF
and control RAW 264.7 macrophages (pBK1.1) were selected
for the present studies (Figure 1A) [10, 12]. MIF−/− mice back-
crossed 8 times on the BALB/c background were obtained
from John David (Harvard Medical School, Boston, MA) [19].
Bone marrow–derived macrophages (BMDMs) were cultured
as described [28]. Animal procedures were approved by the
Ofﬁce Vétérinaire du Canton de Vaud (authorizations 876.7 6
and 877.7) and were performed according to our institution’s
guidelines for animal experiments.
Bacteria, Reagents, and Cytokines
The following panel of laboratory and clinical gram-negative
and gram-positive bacterial strains isolated from septic pa-
tients hospitalized at the Centre Hospitalier Universitaire
Vaudois were used: E. coli O111:B4 (smooth LPS type), E. coli
J5 (rough LPS type), E. coli O18:K1:H7 (capsule-producing
strain), K. pneumoniae strain Caroli, P. aeruginosa, S. pyo-
genes, S. mitis 205, and S. aureus AW7 and P8. Bacteria were
grown in tryptic soy broth (TSB; Becton Dickinson, Erembo-
degem, Belgium). E. coli O111:B4 LPS was from Sigma-
Aldrich (St Louis, MO), and TNF was from Roche Diagnostics
(Rotkreuz, Switzerland). Recombinant murine MIF was pre-
pared as described [12] and contained <10 pg of endotoxin
per microgram of protein, as determined by an endotoxin
spectrophotometric assay (Endosafe-Portable Test System;
Charles River Laboratories, Charleston, SC).
Assay for Bacterial Phagocytosis and Bacterial Killing
Bacteria were grown overnight in TSB at 37°C, washed in
phosphate-buffered saline, and adjusted to approximately 107
CFU/mL in RPMI 1640 medium containing 10% FCS. Phago-
cytosis and killing assays were performed as previously de-
scribed [29]. Brieﬂy, macrophages were incubated with
bacteria (20 bacteria/macrophage). After 1 hour, extracellular
bacteria were washed away, and macrophages were incubated
for 30 minutes (to assess phagocytosis) or 24 hours (to assess
killing) in the presence of either gentamicin (for all bacterial
strains except S. aureus) or lysostaphin (for S. aureus) to elim-
inate the remaining extracellular bacteria. Cells were lysed,
and the number of intracellular bacteria was determined by
plating serial dilutions of cell lysates on agar plates. Killing
was expressed as the percentage of bacteria recovered after 24
hours, using the formula [(bacterial count at 24 hours)/(bacte-
rial count at 1 hour)] × 100.
Nitric Oxide (NO) and TNF Measurements
A total of 4 × 104 macrophages were plated in 96-well cell-
culture plates containing 200 μL of medium and were then
stimulated with bacteria (106–107 colony-forming units
[CFU]/mL) or with LPS (100 ng/mL). Concentrations of TNF
and of nitrite/nitrate were measured in cell-culture superna-
tants, as described elsewhere [30].
RNA Analysis
Total RNA was isolated using the TriZol reagent (Invitrogen,
Basel, Switzerland). Expression of TNF and glyceraldehyde-3-
332 • JID 2013:207 (15 January) • Roger et al
phosphate dehydrogenase messenger RNA (mRNA) was as-
sessed by Northern blotting, using speciﬁc complementary
DNA probes [15].
Electrophoretic Mobility Shift Assay
A total of 2 μg of nuclear extracts were incubated for 15
minutes at room temperature with a radiolabeled consensus
NF-κB probe (Santa Cruz, Santa Cruz, CA) and analyzed by
an electrophoretic mobility shift assay, as described elsewhere
[31].
Luciferase Assays
RAW 264.7 macrophages were transiently cotransfected with
the NF-κB–pGL2 luciferase vector and the Renilla pRL-TK
vector (Promega, Dübendorf, Switzerland). Cells were incubat-
ed for 18 hours with LPS (100 ng/mL) or E. coli O111 (108
CFU/mL). Luciferase and Renilla luciferase activities were
measured using the Dual-Luciferase Reporter Assay System
(Promega) [32]. Results were expressed as relative luciferase
activity (ratio of luciferase to Renilla luciferase activity).
Klebsiella Pneumoniae Pneumonia Model
K. pneumoniae (150–350 CFUs) were injected intranasally into
MIF+/+ and MIF−/− BALB/c mice [30]. Severity scores, body
weight, and survival were monitored once daily up to day 30.
The severity score was graded as follows: grade 1, rufﬂed fur;
grade 2, rufﬂed fur plus mobility disturbance, conjunctivitis,
or diarrhea; grade 3, rufﬂed fur, plus mobility disturbance,
plus either conjunctivitis or diarrhea; grade 4, moribund; and
grade 5, death. In selected experiments, mice were euthanized
3 days after bacterial challenge. Lungs were collected, and bac-
terial loads were determined by plating serial dilutions of lung
homogenates onto agar plates.
Statistical Analysis
Comparisons between groups were assessed using analysis of
variance and the Student t test. Survival data were presented
as Kaplan-Meier curves and time to death in the treatment
groups were compared using the log-rank sum test. Two-sided
P values of less than .05 were considered to indicate statistical
signiﬁcance. Analyses were performed using PRISM version
5.0 (GraphPad Software, La Jolla, CA).
RESULTS
Impaired Killing of Gram-Negative Bacteria in MIF-Deﬁcient
Macrophages
To examine whether MIF affected the phagocytosis and killing
of bacteria by macrophages, control and MIF-deﬁcient RAW
264.7 macrophages were exposed to a panel of gram-negative
bacteria (E. coli strains O111, O18, and J5; K. pneumoniae;
Figure 1. Impaired killing of gram-negative bacteria in macrophage
migration inhibitory factor (MIF)–deﬁcient macrophages. Western blot
analysis of MIF content in control (pBK1.1) and MIF-deﬁcient (AS 2.8
and AS 2.23) RAW 264.7 macrophages obtained as described in Materi-
als and Methods (A). Control (black bars) and MIF-deﬁcient (open and
hatched bars) macrophages (B and C) and MIF+/+ (black bars) and MIF−/−
(white bars) bone marrow–derived macrophages (BMDMs; D) were
exposed to Escherichia coli O111, E. coli O18, E. coli J5, Klebsiella pneu-
moniae, Pseudomonas aeruginosa, Streptococcus mitis 205, Staphylococ-
cus aureus AW7, or S. aureus P8. Phagocytosis (B and D) and killing (C
and D) of bacteria were quantiﬁed as described in Materials and
Methods. Data are mean ± SD of 4 determinations from 1 representative
experiment out of 3. *E. coli O111: P = .04 and 0.03; E. coli O18, E. coli
J5, and K. pneumoniae: P < .005 for AS 2.8 and AS 2.23 versus pBK 1.1,
respectively (C). *P = .007 versus MIF+/+ BMDMs (D).
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and P. aeruginosa) and gram-positive bacteria (S. mitis and
S. aureus strains AW7 and P8). After 1 hour, the mean number
of bacteria taken up by control RAW 264.7 macrophages
(5 × 105 cells) ranged between 104 and 106 CFU for all bacterial
strains except K. pneumoniae (102 CFU). As shown in Figure 1B,
the numbers of bacteria phagocytosed by MIF-deﬁcient (AS 2.8
and AS 2.23) and control RAW 264.7 macrophages were
similar for all the bacterial strains tested.
Bacterial killing by macrophages was assessed after 24 hours
of incubation. Control macrophages killed bacteria with
various degrees of efﬁciency. The proportion of ingested bac-
teria killed by macrophages was much higher for gram-
negative organisms (P. aeruginosa, 97%; E. coli O18, 95%; K.
pneumoniae, 89%; E. coli O111, 48%; and E. coli J5, 52%) than
for gram-positive organisms (S. aureus P8, 33%; S. mitis, 33%;
and S. aureus AW7, 24%; Figure 1C). MIF-deﬁcient RAW
264.7 macrophages exhibited a severe impairment of the ca-
pacity to kill enteric gram-negative bacteria. The numbers of
recovered bacteria were 4–6-fold higher in MIF-deﬁcient than
control RAW 264.7 macrophages (E. coli O111: P = .04 and
P = .03 for MIF-deﬁcient AS 2.8 and AS 2.23 macrophages,
respectively, vs control macrophages; E. coli O18, E. coli J5,
and K. pneumoniae: P < .005). In contrast, MIF-deﬁcient mac-
rophages did not exhibit defective killing capacity toward
gram-negative nonfermenters (P. aeruginosa) or gram-positive
cocci (S. mitis and S. aureus; Figure 1C). To conﬁrm these
ﬁndings, we performed similar experiments with MIF−/−
BMDMs exposed to either E. coli or S. aureus. Like in RAW
264.7 macrophages, ingestion of E. coli and S. aureus did not
differ between MIF+/+ and MIF−/− BMDMs, yet killing of E. coli
(but not S. aureus) was reduced 2.8-fold in MIF−/− BMDMs,
compared with MIF+/+ BMDMs (P = .007; Figure 1D).
We then performed add-back experiments to determine
whether the addition of exogenous recombinant MIF protein
would restore the bacterial killing capacity of MIF-deﬁcient
macrophages. MIF-deﬁcient RAW 264.7 macrophages were in-
cubated for 18 hours with recombinant MIF prior to exposure
to E. coli. As anticipated, the phagocytosis of E. coli remained
unchanged in cells preincubated with recombinant MIF
(Figure 2A). In contrast, MIF supplementation in MIF-deﬁ-
cient macrophages increased the killing of E. coli by 2.5–4-
fold (P = .05 and P = .008 for MIF-deﬁcient AS 2.8 and AS
2.23 macrophages, respectively; Figure 2B). Together, these
results indicated that MIF deﬁciency in macrophages did not
affect the ingestion of either gram-negative or gram-positive
bacteria but impaired the killing of enteric gram-negative bac-
teria (E. coli and K. pneumoniae).
Decreased TNF Production by MIF-Deﬁcient Macrophages
Stimulated With Gram-Negative Bacteria or LPS
On activation by microbes or microbial-derived products,
macrophages produce and release a large panel of cytokines
and antimicrobial molecules that play a critical role in the ini-
tiation of the innate and adaptive host defense responses. To
investigate the mechanism underlying the defective bacterici-
dal activity of MIF-deﬁcient macrophages, we ﬁrst looked at
the production of NO, which is a critical component of the
host microbicidal innate immune armamentarium. Control
and MIF-deﬁcient RAW 264.7 macrophages produced similar
amounts of NO 2, 8, and 24 hours after stimulation with
either E. coli O111 or K. pneumoniae (Figure 3). We then ex-
amined the production of TNF, which is a pivotal proinﬂam-
matory cytokine rapidly released by innate immune cells on
microbial invasion. TNF production was massively downregu-
lated in MIF-deﬁcient RAW 264.7 macrophages after stimula-
tion with gram-positive bacteria (E. coli O111, E. coli O18,
K. pneumoniae, or P. aeruginosa) or LPS (Figure 4) but not
after exposure to gram-positive bacteria (S. pyogenes, S. mitis,
or S. aureus; data not shown). Addition of recombinant mouse
TNF did not enhance phagocytosis, but it restored the bacteri-
cidal capacity of MIF-deﬁcient AS 2.8 and AS 2.23 macrophag-
es (P = .01 and P = .0008, respectively; Figure 5). Together,
these results suggest that reduced TNF production was associ-
ated with and may have accounted for the impaired anti–gram-
negative bactericidal activity of MIF-deﬁcient macrophages.
Reduced Intracellular Signaling in MIF-Deﬁcient
Macrophages Exposed to Gram-Negative Bacteria
Given that MIF deﬁciency is associated with reduced expres-
sion of TLR4 in the macrophage [12, 13], we then studied the
signal transduction of MIF-deﬁcient macrophages on activa-
tion with gram-negative bacteria. In control RAW 264.7 mac-
rophages, TNF mRNA expression peaked 2 hours after
stimulation with E. coli or K. pneumoniae (Figure 6A). Consis-
tent with the data on TNF production (Figure 4), the peak of
TNF mRNA was delayed (reached only after 8 hours) and
markedly reduced (5-fold) in MIF-deﬁcient RAW 264.7 mac-
rophages (Figure 6A). Induction of Tnf gene transcription on
activation of TLRs by gram-negative bacteria requires nuclear
translocation of NF-κB. We therefore quantiﬁed by electro-
phoretic mobility shift assay the NF-κB DNA binding in
nuclear extracts of RAW 264.7 macrophages. Thirty minutes
after stimulation with E. coli, NF-κB DNA-binding activity in-
creased 9-fold in control macrophages but only 2.2–3.5-fold
in MIF-deﬁcient AS 2.8 and AS 2.23 macrophages (Figure 6B).
To conﬁrm that reduced nuclear localization of NF-κB affect-
ed NF-κB–dependent transcription, we quantiﬁed NF-κB–
mediated transcriptional activity in RAW 264.7 macrophages
transfected with a NF-κB–driven luciferase reporter plasmid.
LPS and E. coli increased luciferase activity more strongly in
control macrophages than in MIF-deﬁcient macrophages
(LPS: 10-fold vs 3.8-fold, P = .0001; E. coli: 5.7-fold vs 2.3-fold,
P = .02; Figure 6C).
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Increased Mortality of Gram-Negative Pneumonia in
MIF-Deﬁcient Mice
Given that MIF deﬁciency impaired the killing of E. coli and
K. pneumoniae, we thought to evaluate the outcome of MIF+/+
and MIF−/− mice in a gram-negative pneumonia sepsis model
induced by the intranasal inoculation of K. pneumoniae. The
impact of MIF-targeted therapy in E. coli sepsis has been pre-
viously reported [20, 33]. Severity scores (Figure 7A), body
weight losses (Figure 7B), bacterial loads (Figure 7C), and
mortality (Figure 7D) were signiﬁcantly higher in MIF−/− than
in MIF+/+ mice. These data showed that the defective bacterici-
dal activity of MIF-deﬁcient macrophages against gram-nega-
tives in vitro translated into increased morbidity and mortality
of gram-negative sepsis in vivo, supporting the idea that MIF
is an important effector molecule of innate immunity.
DISCUSSION
Constitutive expression of MIF was found to be critical for the
killing of enteric gram-negative bacteria by macrophages and
for host defenses against gram-negative pneumonia. TLR4 sig-
naling pathway was defective in MIF-deﬁcient macrophages as
shown by reduced NF-κB activity and production of proin-
ﬂammatory cytokines. These observations provided a molecu-
lar basis for the innate immune defects of MIF-deﬁcient cells
or animals (present study) or associated with the use of neu-
tralizing anti-MIF antibodies or MIF inhibitors in MIF
Figure 5. Tumor necrosis factor (TNF) complementation restored the
bactericidal activity of macrophage migration inhibitory factor (MIF)–deﬁ-
cient macrophages. MIF-deﬁcient macrophages were cultured for 18
hours with (black bars) or without (open bars) TNF (10 ng/mL) before
exposure to E. coli O111. Phagocytosis (A) and killing (B) of bacteria
were quantiﬁed as described in Material and Methods. Data are mean ±
SD of 4 determinations from 1 representative experiment representative
out of 2. *P = .01 and P = .0008 for AS 2.8 and AS 2.23.
Figure 3. Normal nitric oxide production by macrophage migration in-
hibitory factor (MIF)–deﬁcient macrophages. Control (pBK1.1, black bars)
and MIF-deﬁcient (AS 2.8 and AS 2.23, open and hatched bars) macro-
phages were cultured for 18 hours with 108 colony-forming units (CFU)/
mL Escherichia coli O111 or K. pneumoniae. Concentrations of nitrites/
nitrates in cell-culture supernatants were measured using the Griess
reagent. Data are mean ± SD of triplicates from 1 representative experi-
ment out of 2.
Figure 2. Recombinant macrophage migration inhibitory factor (MIF)
protein restored the capacity of MIF-deﬁcient macrophages to kill Escher-
ichia coli. MIF-deﬁcient macrophages were cultured 18 hours with (black
bars) or without (open bars) recombinant MIF (100 ng/mL) and then
exposed to E. coli O111 (MOI 20). Phagocytosis (A) and killing (B) of
bacteria were quantiﬁed as described in Materials and Methods. Data
are mean ± SD of 4 determinations from 1 representative experiment out
of 2. *P = .05 and P = .008 for AS 2.8 and AS 2.23, respectively.
Figure 4. Decreased tumor necrosis factor (TNF) production by macro-
phage migration inhibitory factor (MIF)–deﬁcient macrophages stimulated
with lipopolysaccharide (LPS) or gram-negative bacteria. Control (pBK1.1,
black bars) and MIF-deﬁcient (AS 2.8 and AS 2.23, open and hatched
bars) macrophages were stimulated with LPS (100 ng/mL) or with Escher-
ichia coli O111, E. coli O18, Pseudomonas aeruginosa, or Klebsiella
pneumoniae (106–108 colony-forming units (CFU)/mL). TNF concentrations
were measured in cell-culture supernatants harvested 4 hours after stim-
ulation. Data are mean ± SD of triplicates from 1 representative experi-
ment out of 3.
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sufﬁcient cells or animals [12, 16, 20, 34]. These data are also
in line with our previous ﬁndings that MIF-deﬁcient macro-
phages displayed a phenotype characterized by hyporespon-
siveness to LPS due to a reduced expression of TLR4 [12, 13].
The observation that MIF was dispensable for the phagocy-
tosis of a broad range of bacteria by innate immune cells was
surprising for 3 main reasons. First, considering that proin-
ﬂammatory cytokines promote bacterial uptake by phagocytes,
one might have expected MIF-deﬁcient macrophages to
exhibit impaired phagocytic capacity in the context of reduced
proinﬂammatory autocrine activities. Yet, the present results
are in line with the observation that TLR4-deﬁcient BMDMs
and dendritic cells or alveolar macrophages take up Salmonella
Typhimurium and E. coli as efﬁciently as wild-type cells [35,
36]. Second, work by Swant et al showed that MIF promotes
Rho GTPase-dependent signaling and stress ﬁber formation in
ﬁbroblasts [37]. Given that Rho-GTPase signaling controls
actin polymerization and cytoskeleton reorganization during
particle ingestion, one might have expected MIF-deﬁcient
macrophages to also exhibit phagocytosis defects. But this was
not the case, a ﬁnding in agreement with the results published
by Wiersinga et al that showed no impact of MIF on phagocy-
tosis of gram-negative bacteria (ie, Burkholderia pseudomallei)
by macrophages and neutrophils [38]. These results suggest
that the impact of MIF on Rho-GTPase may be limited to
certain members of the Rho family. Alternatively, MIF-
mediated effects on Rho-GTPase signaling might be cell spe-
ciﬁc. Third, recombinant MIF has been shown previously to
augment the uptake of ﬂuorescent latex beads by RAW 264.7
macrophages [39]. However, there are inherent differences in
Figure 7. Severity scores, body weight losses, bacterial counts, and
mortality in a Klebsiella pneumoniae pneumonia model. Macrophage mi-
gration inhibitory factor (MIF)+/+ and MIF−/− mice were inoculated intra-
nasally with 340 (A, B, and D; n = 7 mice per group) or 160 (C; n = 4
MIF+/+ and 6 MIF−/− mice) colony-forming units (CFU) of K. pneumoniae.
A, Severity scores (*P < .05). B, Percentage body weight losses (*P = .04).
C, Bacterial counts (mean, 138 CFU/g [range, 5–580 CFU/g] vs 3080
CFU/g [range, 103–4 × 107 CFU/g]; P = .01) in lungs harvested 3 days after
infection. D, Kaplan–Meier survival curves (P = .02).
Figure 6. Impaired intracellular signaling in macrophage migration in-
hibitory factor (MIF)–deﬁcient macrophages stimulated with gram-nega-
tive bacteria. A, Northern blot analyses of tumor necrosis factor (TNF)
and glyceraldehyde-3-phosphate dehydrogenase messenger RNA expres-
sion in control and MIF-deﬁcient macrophages cultured with 108 colony-
forming units (CFU)/mL Escherichia coli O111 or Klebsiella pneumoniae.
Results are representative of two experiments. B, Electrophoretic mobility
shift assay of nuclear factor κB (NF-κB) DNA binding activity in nuclear
extracts of control and MIF-deﬁcient macrophages cultured with E. coli
O111 (108 CFU/mL). C, NF-κB–driven luciferase activity in control
(pBK1.1, black bars) and MIF-deﬁcient (AS 2.8, open bars) macrophages
cultured for 18 hours with lipopolysaccharide (LPS; 100 ng/mL) or E. coli
O111 (108 CFU/mL). Data are mean ± SD of triplicates from 1 representa-
tive experiment out of 3 (*P = .0001 and P = .02).
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the sensing and uptake of inert particles or live bacteria by
phagocytes [40]. Consistent with the present data, phagocyto-
sis of inert microspheres was similar in wild-type, TLR2-TLR4
double-knockout or MyD88−/− macrophages [41].
TLRs are recruited to phagosomes and participate in the
sensing of microbial pathogens [42]. The role played by TLRs
in the maturation of phagosomes is controversial. On phago-
cytosis of E. coli or S. aureus, TLR2-, TLR4-, and MyD88-
deﬁcient macrophages acquire lysosomal markers at slower
rates than wild-type macrophages, suggesting that TLR signal-
ing was important for the maturation of phagosomes [41].
However, other investigators reported that phagosome matura-
tion or phagosome-lysosome fusion were independent of TLR
signaling [43]. The facts that MIF deﬁciency was associated
with reduced TLR4 expression, NF-κB activity, cytokine pro-
duction, and killing of gram-negative (but not gram-positive)
bacteria support a role for TLR signaling in the control of
phagolysosome formation or bactericidal activity.
Cytokine complementation with MIF (Figure 2), TNF
(Figure 5), or interferon (IFN-γ; data not shown) increased
the bactericidal activity of MIF-deﬁcient macrophages without
modiﬁcation of the phagocytic activity, conﬁrming that pha-
gocytosis and bactericidal activity are regulated via different
signaling pathways [44]. Importantly, these results suggest that
MIF restored the bactericidal activity of macrophages via a MIF
receptor–dependent autocrine/paracrine mechanism [2–5] and
not via an intracellular JAB1-mediated pathway [10].
At ﬁrst glance, the fact that MIF deﬁciency affected the
killing of enteric (E. coli and K. pneumoniae) but not of non-
fermentative (P. aeruginosa) gram-negative bacteria may appear
surprising. However, we also observed that MIF−/− mice were
highly susceptible to pneumonia caused by K. pneumoniae,
whereas MIF−/− mice were reported to be more resistant than
wild-type mice to P. aeruginosa lung infection [19]. Likewise,
mice deﬁcient in Toll/IL-1R domain-containing adaptor
protein, a key adaptor molecule of TLR1, TLR2, TLR4, and
TLR6 signaling, were shown to be resistant to P. aeruginosa
pneumonia but highly susceptible to K. pneumoniae pneumo-
nia [45]. Interestingly, MIF deﬁciency did not affect the killing
of gram-positive bacteria. As previously reported, MIF deﬁ-
ciency did not impair TLR2 expression in macrophages [12].
The critical role played by TLR2 in the sensing of gram-positive
bacteria and host responses to subcomponents of peptidoglycan
may explain why innate immune responses to gram-positive
bacteria were unaffected in MIF-deﬁcient macrophages.
Previous studies have revealed cell-speciﬁc differences re-
garding the involvement of TLRs in host defenses against
gram-negative bacteria. Indeed, TLR4 deﬁciency profoundly
affected the killing of S. Typhimurium by bone marrow-
deived dendritic cells whereas it did not impact the bacterici-
dal activity of bone marrow-derived dendritic cells [35].
Similarly, we observed that the uptake and killing of E. coli
were comparable in MIF−/− and wild-type BMDMs (data not
shown). Moreover, the absence of MIF did not impact NO
production following bacterial infection in vitro and in vivo
([21, 22] and present study), while it had a negative impact on
NO production and susceptibility to parasitic infections
caused by Leishmania major and Taenia crassiceps [46–48]. In
a similar fashion, inducible nitric oxide synthase (NOS2)
knockdown modestly affected the killing of E. coli by macro-
phages but had a major negative impact on parasitic infections
[49, 50]. Interestingly, thioglycollate-elicited MIF−/− macro-
phages stimulated with LPS and IFN-γ had been shown previ-
ously to release higher levels of NO than MIF+/+ macrophages
[19]. The use of various subsets of macrophages, of stimuli en-
gaging different sets of innate immune receptors, or of cells
with different genetic backgrounds may explain these discrep-
ancies. Together, these results nicely illustrate the high degree
of speciﬁcity of the host innate immune defenses in terms of
microbial sensing and effector responses even within a given
class of microbial pathogens, such as extracellular gram-
negative bacteria. Genetic studies have also revealed that poly-
morphisms of genes involved in antimicrobial defenses impact
host defenses against infection. Consistent with an important
role played by MIF in innate immunity, recent ﬁndings in
humans indicate that MIF gene polymorphisms were associat-
ed with the susceptibility to and outcome of infectious dis-
eases [25–27].
In conclusion, the present work has revealed an unsuspect-
ed role for MIF in the killing of extracellular gram-negative
bacteria and argues in favor of an intrinsic contribution of
MIF in innate immune defenses against bacterial infection.
This observation conﬁrms and extends previous studies
strongly supporting the view that MIF helps preserving host
integrity against infectious threats.
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